AnaptysBio (ANAB) Sees Strong Trading Volume After Analyst Upgrade
Shares of AnaptysBio Inc (NASDAQ:ANAB) saw strong trading volume on Monday after Royal Bank of Canada raised their price target on the stock to $108.00. Royal Bank of Canada currently has an outperform rating on the stock. 1,927,700 shares were traded during trading, an increase of 770% from the previous session’s volume of 221,524 shares.The stock last traded at $91.96 and had previously closed at $88.75.
A number of other equities research analysts have also recently weighed in on ANAB. Zacks Investment Research upgraded AnaptysBio from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research note on Tuesday, August 22nd. Wedbush restated a “positive” rating and issued a $82.00 price target (up previously from $75.00) on shares of AnaptysBio in a research note on Tuesday, November 7th. Stifel Nicolaus restated a “buy” rating and issued a $35.00 price target on shares of AnaptysBio in a research note on Tuesday, September 12th. Robert W. Baird set a $69.00 price target on AnaptysBio and gave the company a “buy” rating in a research note on Wednesday, October 11th. Finally, Credit Suisse Group increased their price target on AnaptysBio from $38.00 to $85.00 and gave the company an “outperform” rating in a research note on Tuesday, October 10th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. AnaptysBio presently has a consensus rating of “Buy” and a consensus target price of $88.00.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Perceptive Advisors LLC grew its holdings in AnaptysBio by 3.2% in the 3rd quarter. Perceptive Advisors LLC now owns 982,269 shares of the biotechnology company’s stock valued at $34,330,000 after buying an additional 30,000 shares in the last quarter. VHCP Management II LLC acquired a new position in AnaptysBio in the 3rd quarter valued at $5,856,000. Evercore Wealth Management LLC acquired a new position in AnaptysBio in the 3rd quarter valued at $100,000. California State Teachers Retirement System grew its holdings in AnaptysBio by 104.2% in the 3rd quarter. California State Teachers Retirement System now owns 19,400 shares of the biotechnology company’s stock valued at $678,000 after buying an additional 9,900 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. grew its holdings in AnaptysBio by 69.3% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 32,846 shares of the biotechnology company’s stock valued at $1,148,000 after buying an additional 13,444 shares in the last quarter. 75.48% of the stock is currently owned by hedge funds and other institutional investors.
AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.02. sell-side analysts anticipate that AnaptysBio Inc will post -1.72 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “AnaptysBio (ANAB) Sees Strong Trading Volume After Analyst Upgrade” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/anaptysbio-anab-sees-strong-trading-volume-after-analyst-upgrade/1773618.html.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.